Nasdaq

Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

As of December 31, 2022, the Company had cash, cash equivalents and marketable securities totaling $118.4 million. Forward-Looking StatementsThis press release contains forward-looking statements that ...
Seeking Alpha

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (LRMR) (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex ...
Nasdaq

Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 ...

BALA CYNWYD, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Seeking Alpha

Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in Friedreich’s ataxia patients is ongoing and proceeding in line with the Company’s planned timeline Larimar (LRMR) expects to ...